The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
The mighty mouse: genetically engineered mouse models in cancer drug development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Tumorigenic study on hepatocytes coexpressing SV40 with Ras
Sun, B., Chen, M., Hawks, C. L., Hornsby, P. J., & Wang, X. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20137 · Cited by 6
RetractedStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Angiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113
Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
Artandi, S. E., Chang, S., Lee, S.-L., Alson, S., Gottlieb, G. J., Chin, L., & DePinho, R. A. (2000) · Nature · doi:10.1038/35020592 · Cited by 1,085
Self-citationEffects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Differentiation and reversal of malignant changes in colon cancer through PPARγ
Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., et al. (1998) · Nature Medicine · doi:10.1038/2030 · Cited by 988
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Self-citationMYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Suppression of intestinal neoplasia by DNA hypomethylation
Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Edward Jung, W., Li, E., Weinberg, R. A., & Jaenisch, R. (1995) · Cell · doi:10.1016/0092-8674(95)90329-1 · Cited by 710
Scaling down imaging: molecular mapping of cancer in mice
Weissleder, R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc701 · Cited by 708
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 663
Epidermal growth factor receptor and Ink4a/Arf
Bachoo, R. M., Maher, E. A., Ligon, K. L., Sharpless, N. E., Chan, S. S., You, M. J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00046-6 · Cited by 652
Self-citationActivators of the nuclear receptor PPARγ enhance colon polyp formation
Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G. A., U, T. M., Baird, S. M., Thomazy, V. A., & Evans, R. M. (1998) · Nature Medicine · doi:10.1038/2042 · Cited by 587
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
Bardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 581
Self-citationBoolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., et al. (1996) · PubMed · Cited by 545
(2003) · PubMed · Cited by 523
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors
Brinster, R. L., Chen, H. Y., Messing, A., van Dyke, T., Levine, A. J., & Palmiter, R. D. (1984) · Cell · doi:10.1016/0092-8674(84)90367-2 · Cited by 483
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478
Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. J., & Lubet, R. A. (2000) · PubMed · Cited by 478
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Self-citationRequirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., et al. (2001) · Nature Medicine · doi:10.1038/84691 · Cited by 418
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
Self-citationTargeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27 Kip1 Activity
Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7011 · Cited by 395
Cdc2–cyclin E complexes regulate the G1/S phase transition
Aleem, E., Kiyokawa, H., & Kaldis, P. (2005) · Nature Cell Biology · doi:10.1038/ncb1284 · Cited by 383
Cancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
Contributions of Human Tumor Xenografts to Anticancer Drug Development
Sausville, E. A., & Burger, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3627 · Cited by 348
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
Roberts, T. G. (2004) · JAMA · doi:10.1001/jama.292.17.2130 · Cited by 319
Transgenic Models of Tumor Development
Adams, J. M., & Cory, S. (1991) · Science · doi:10.1126/science.1957168 · Cited by 280
Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice
Quaife, C. J., Pinkert, C. A., Ornitz, D. M., Palmiter, R. D., & Brinster, R. L. (1987) · Cell · doi:10.1016/0092-8674(87)90710-0 · Cited by 262
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer, F. A., Meyer, W. H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1815 · Cited by 235
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1
Martín, A., Odajima, J., Hunt, S. L., Dubus, P., Ortega, S., Malumbres, M., & Barbacid, M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.006 · Cited by 223
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
Peterson, J. K., & Houghton, P. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.003 · Cited by 223
Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, P., Pluda, J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.120 · Cited by 223
Fluorescence Molecular Imaging of Small Animal Tumor Models
Graves, E., Weissleder, R., & Ntziachristos, V. (2004) · Current Molecular Medicine · doi:10.2174/1566524043360555 · Cited by 213
Boxer, R. B., Jang, J. W., Sintasath, L., & Chodosh, L. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.013 · Cited by 178
Responses and toxic deaths in Phase I clinical trials
Decoster, G., Stein, G., & Holdener, E. E. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057716 · Cited by 170
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
Self-citationMutation and expression of the p53 gene in human malignant melanoma
Albino, A. P., Vidal, M. J., McNutt, N. S., Shea, C. R., Prieto, V. G., Nanus, D. M., Palmer, J. M., & Hayward, N. K. (1994) · Melanoma Research · doi:10.1097/00008390-199402000-00006 · Cited by 166
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.
Okami, K., Wu, L. J., Riggins, G. J., Cairns, P., Goggins, M., Evron, E., Halachmi, N., Ahrendt, S. A., Reed, A. L., Hilgers, W., et al. (1998) · PubMed · Cited by 163
Why we're losing the war on cancer (and how to win it).
Leaf, C. (2004) · PubMed · Cited by 156
Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R. A., Clark, J. S., Spiegelman, B. M., Kim, H. T., Mayer, R. J., & Fuchs, C. S. (2002) · The Cancer Journal · doi:10.1097/00130404-200209000-00010 · Cited by 154
Self-citationMcCabe, M. T., Low, J. A., Daignault, S. D., Imperiale, M. J., Wojno, K. J., & Day, M. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2020 · Cited by 149
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M. L., et al. (1996) · PubMed · Cited by 137
A mouse model of human oral-esophageal cancer
Opitz, O. G., Harada, H., Suliman, Y., Rhoades, B., Sharpless, N. E., Kent, R., Kopelovich, L., Nakagawa, H., & Rustgi, A. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15324 · Cited by 128
Self-citationBoth products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo
Sharpless, N. E., Kannan, K., Xu, J., Bosenberg, M., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206809 · Cited by 116
Self-citationAbsence of p53 Gene Mutations in Cutaneous Melanoma
Lübbe, J., Reichel, M., Burg, G., & Kleihues, P. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12381544 · Cited by 113
A mouse model of human oral-esophageal cancer
Opitz, O. G., Harada, H., Suliman, Y., Rhoades, B., Sharpless, N. E., Kent, R., Kopelovich, L., Nakagawa, H., & Rustgi, A. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215324 · Cited by 106
Self-citationOmer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., et al. (2000) · PubMed · Cited by 105
Mitsiades, C. S., Mitsiades, N., Bronson, R. T., Chauhan, D., Munshi, N. C., Treon, S. P., Maxwell, C. A., Pilarski, L. M., Hideshima, T., Hoffman, R. M., et al. (2003) · PubMed · Cited by 102
Castresana, J. S., Rubio, M., Seizinger, B. R., Vázquez, J. J., Idoate, M. A., Sober, A. J., & Barnhill, R. L. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550407 · Cited by 99
Tassone, P., Neri, P. E., Burger, R., Savino, R., Shammas, M. A., Catley, L. P., Podar, K., Chauhan, D., Masciari, S., Gozzini, A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2611 · Cited by 91
Are large clinical trials in rapidly lethal diseases usually unethical?
Horrobin, D. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12571-8 · Cited by 63
Hansma, A. H. G., Broxterman, H. J., van der Horst, I., Yuana, Y., Boven, E., Giaccone, G., Pinedo, H. M., & Hoekman, K. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi318 · Cited by 61
Animal models for studying the action of topoisomerase I targeted drugs
Thompson, J., Stewart, C. F., & Houghton, P. J. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00143-2 · Cited by 60
The Occurrence of a Dominant Spotting Mutation in the House Mouse
Little, C. C., & Cloudman, A. M. (1937) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.23.10.535 · Cited by 57
Sotillo, R., Renner, O., Dubus, P. R., Ruíz-Cabello, J., Martín‐Caballero, J., Barbacid, M., Carnero, A., & Malumbres, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4195 · Cited by 56
Reporter mice and drug discovery and development
Maggi, A. C., & Ciana, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1661 · Cited by 54
Phase II study of 5-azacytidine in solid tumors.
Weiss, A. J., Metter, G. E., Nealon, T. F., et al. (1977) · PubMed · Cited by 49
Sun, B., Chen, M., Hawks, C. L., Pereira‐Smith, O. M., & Hornsby, P. J. (2005) · Neoplasia · doi:10.1593/neo.05172 · Cited by 48
Davis, D. W., Shen, Y., Mullani, N. A., Wen, S., Herbst, R. S., O’Reilly, M. S., Abbruzzese, J. L., & McConkey, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0736-3 · Cited by 35
Zhang, Z., Wang, Y., Lantry, L. E., Kastens, E., Liu, G., Hamilton, A. D., Sebti, S. M., Lubet, R. A., & You, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206630 · Cited by 33
Development and characterization of pediatric osteosarcoma xenografts.
Meyer, W. H., Houghton, J. A., Houghton, P. J., Webber, B. L., Douglass, E. C., & Look, A. T. (1990) · PubMed · Cited by 29
Soff, G. A., Wang, H., Cundiff, D. L., Jiang, K., Martone, B. K., RADEMAKER, A. W., Doll, J. A., & Kuzel, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1514 · Cited by 24
Aberrant expression of p53 gene product in malignant melanoma
Rhim, K. J., Hong, S., Hong, W. S., Lee, S. Y., Lee, D. S., & Jang, J. J. (1994) · Journal of Korean Medical Science · doi:10.3346/jkms.1994.9.5.376 · Cited by 7
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Imaging in the era of molecular oncology
Weissleder, R., & Pittet, M. J. (2008) · Nature · doi:10.1038/nature06917 · Cited by 2,364
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Self-citation
Metadata
- Authors
- Sharpless, N. E., & DePinho, R. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-18
- Volume
- 5
- Issue
- 9
- Pages
- 741-754
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2001679453
- Cited by
- 661
- References
- 98
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.